Complete financial analysis of PTC Therapeutics, Inc. (PTCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Goodbaby International Holdings Limited (1086.HK) Income Statement Analysis – Financial Results
- OMRON Corporation (OMRNF) Income Statement Analysis – Financial Results
- LleidaNetworks Serveis Telemàtics, S.A. (LLN.MC) Income Statement Analysis – Financial Results
- Sportsoul Co.,Ltd. (001300.SZ) Income Statement Analysis – Financial Results
- Magellan Financial Group Limited (MGLLF) Income Statement Analysis – Financial Results
PTC Therapeutics, Inc. (PTCT)
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.71M | 36.77M | 22.96M | 31.33M | 28.78M | 98.96M |
| Cost of Revenue | 65.49M | 44.68M | 32.33M | 18.94M | 12.14M | 12.67M | 4.58M | 117.63M | 121.82M | 79.84M | 54.88M | -5.17M | 0.00 |
| Gross Profit | 872.34M | 654.12M | 506.27M | 361.82M | 294.85M | 252.06M | 189.82M | -34.93M | -85.05M | -56.88M | -23.55M | 33.95M | 98.96M |
| Gross Profit Ratio | 93.02% | 93.61% | 94.00% | 95.03% | 96.05% | 95.21% | 97.65% | -42.23% | -231.33% | -247.68% | -75.17% | 117.95% | 100.00% |
| Research & Development | 666.56M | 651.50M | 540.68M | 477.64M | 257.45M | 171.98M | 117.46M | 117.63M | 121.82M | 79.84M | 54.88M | 46.14M | 58.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 332.54M | 326.00M | 285.77M | 245.16M | 202.54M | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Other Expenses | 0.00 | 116.55M | 54.75M | 36.89M | 27.65M | 129.00K | -1.28M | -1.21M | -465.00K | -213.00K | 37.51K | 1.78M | 461.36K |
| Operating Expenses | 1.31B | 1.09B | 881.21M | 759.70M | 487.64M | 348.41M | 254.11M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Cost & Expenses | 1.29B | 1.14B | 913.54M | 778.64M | 499.78M | 361.08M | 258.68M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Interest Income | 0.00 | 90.87M | 86.02M | 56.35M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 129.18M | 90.87M | 86.02M | 56.35M | 12.49M | 12.55M | 12.09M | 8.28M | 2.37M | 1.18M | 0.00 | 0.00 | 2.44M |
| Depreciation & Amortization | 236.59M | 128.84M | 71.52M | 49.58M | 36.06M | 26.09M | 17.68M | 3.29M | 2.88M | 2.24M | 2.40M | 2.70M | 2.87M |
| EBITDA | -330.34M | -367.78M | -374.44M | -297.00M | -191.38M | -89.47M | -46.61M | -128.77M | -164.25M | -97.18M | -43.00M | -24.10M | 33.45M |
| EBITDA Ratio | -35.22% | -53.32% | -70.20% | -59.83% | -38.04% | -20.45% | -25.16% | -159.67% | -454.58% | -432.93% | -136.85% | -83.76% | 33.80% |
| Operating Income | -349.40M | -439.93M | -374.94M | -397.88M | -192.80M | -115.69M | -64.29M | -132.06M | -167.13M | -99.41M | -45.40M | -26.81M | 30.58M |
| Operating Income Ratio | -37.26% | -62.95% | -69.62% | -104.49% | -62.80% | -43.70% | -33.07% | -159.67% | -454.58% | -432.93% | -144.92% | -93.15% | 30.90% |
| Total Other Income/Expenses | -346.71M | -147.56M | -143.40M | -59.36M | -47.13M | -12.43M | -13.37M | -9.48M | -2.83M | 967.00K | -6.18M | 573.00K | -1.98M |
| Income Before Tax | -696.11M | -587.49M | -518.34M | -402.93M | -239.93M | -128.11M | -77.67M | -141.54M | -169.96M | -98.45M | -51.57M | -26.24M | 28.60M |
| Income Before Tax Ratio | -74.23% | -84.07% | -96.24% | -105.82% | -78.16% | -48.39% | -39.95% | -171.14% | -462.28% | -428.72% | -164.63% | -91.16% | 28.90% |
| Income Tax Expense | -69.51M | -28.47M | 5.56M | 35.23M | 11.65M | -29.00K | 1.34M | 569.00K | 485.00K | -4.69M | 6.21M | 1.21M | -2.31M |
| Net Income | -626.60M | -559.02M | -523.90M | -438.16M | -251.58M | -128.08M | -79.00M | -142.11M | -170.45M | -93.75M | -51.57M | -26.24M | 30.90M |
| Net Income Ratio | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.60% | -408.28% | -164.63% | -91.16% | 31.23% |
| EPS | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.85 | 0.00 |
| EPS Diluted | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.11 | 0.00 |
| Weighted Avg Shares Out | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.11M | 34.04M | 33.62M | 31.57M | 12.82M | 14.19M | 14.19M |
| Weighted Avg Shares Out (Dil) | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 23.68M | 23.68M |
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
PTCT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your PTC Therapeutics, Inc. investment
ATTENTION PTCT SHAREHOLDERS: Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
PTC Therapeutics Provides Key Regulatory Updates
Levi & Korsinsky Reminds Shareholders of an Investigation into PTC Therapeutics, Inc. (PTCT) Regarding Potential Securities Fraud Allegations
PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC (PTCT)
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates
PTCT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PTC Therapeutics, Inc. Shareholders Who Lost Money
ATTENTION PTC Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
Source: https://incomestatements.info
Category: Stock Reports